Flow cytometry, utilizing MSC markers CD105, CD73, and CD90 combined with negative expression of hematopoietic lineage markers, has been employed to detect and quantify TA-MSCs in high-grade gliomas [83], primary prostate cancer [72], and gastrointestinal stromal tumor [84]. This evidence concerns the gene THY1 and central nervous system cancer.